Zacks: Analysts Expect Teligent Inc (TLGT) to Post $0.03 Earnings Per Share
Equities research analysts forecast that Teligent Inc (NASDAQ:TLGT) will announce earnings per share (EPS) of $0.03 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Teligent’s earnings. The lowest EPS estimate is $0.01 and the highest is $0.08. Teligent posted earnings of $0.01 per share in the same quarter last year, which would suggest a positive year over year growth rate of 200%. The firm is expected to report its next earnings report on Thursday, July 27th.
According to Zacks, analysts expect that Teligent will report full-year earnings of $0.15 per share for the current year, with EPS estimates ranging from $0.09 to $0.31. For the next financial year, analysts forecast that the firm will report earnings of $0.42 per share, with EPS estimates ranging from $0.25 to $0.62. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Teligent.
Teligent (NASDAQ:TLGT) last posted its quarterly earnings results on Tuesday, March 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $17.90 million for the quarter, compared to analysts’ expectations of $17.97 million. Teligent had a negative return on equity of 0.38% and a negative net margin of 20.85%. The firm’s revenue was up 36.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.02) earnings per share.
Separately, Zacks Investment Research lowered shares of Teligent from a “buy” rating to a “hold” rating in a report on Saturday, February 18th. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $9.67.
Teligent (NASDAQ:TLGT) traded down 0.12% during trading on Friday, reaching $8.25. 335,092 shares of the company’s stock traded hands. The firm’s 50 day moving average is $7.86 and its 200 day moving average is $7.23. The company’s market cap is $439.11 million. Teligent has a 12 month low of $5.04 and a 12 month high of $8.72.
Several large investors have recently modified their holdings of TLGT. Northpointe Capital LLC raised its stake in shares of Teligent by 78.1% in the third quarter. Northpointe Capital LLC now owns 494,778 shares of the company’s stock worth $3,760,000 after buying an additional 217,008 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Teligent by 16.8% in the third quarter. Wells Fargo & Company MN now owns 31,292 shares of the company’s stock worth $238,000 after buying an additional 4,503 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Teligent during the third quarter worth approximately $253,000. Zacks Investment Management bought a new stake in shares of Teligent during the third quarter worth approximately $198,000. Finally, Ardsley Advisory Partners bought a new stake in shares of Teligent during the third quarter worth approximately $266,000. Institutional investors and hedge funds own 66.64% of the company’s stock.
WARNING: “Zacks: Analysts Expect Teligent Inc (TLGT) to Post $0.03 Earnings Per Share” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/05/zacks-analysts-expect-teligent-inc-tlgt-to-post-0-03-earnings-per-share.html.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc and related companies with MarketBeat.com's FREE daily email newsletter.